CoChat
Sign Up
Cited by 80Gut microbiota and healthOral microbiology and periodontitis researchNutritional Studies and Diet

The Human Microbiome in Relation to Cancer Risk: A Systematic Review of Epidemiologic Studies

Open access
Huybrechts, Inge, Zouiouich, Semi, Loobuyck, Astrid, Vandenbulcke, Zeger, Vogtmann, Emily, Pisanu, Silvia, Iguacel, Isabel, Scalbert, Augustin +4 more·2020·Cancer Epidemiology, Biomarkers & Prevention
DOI 10.1158/1055-9965.epi-20-0288PMC PMC7541789
Open this paper in CoChat — free accountOpen PDF

Abstract

The microbiome has been hypothesized to play a role in cancer development. Because of the diversity of published data, an overview of available epidemiologic evidence linking the microbiome with cancer is now needed. We conducted a systematic review using a tailored search strategy in Medline and EMBASE databases to identify and summarize the current epidemiologic literature on the relationship between the microbiome and different cancer outcomes published until December 2019. We identified 124 eligible articles. The large diversity of parameters used to describe microbial composition made it impossible to harmonize the different studies in a way that would allow meta-analysis, therefore only a qualitative description of results could be performed. Fifty studies reported differences in the gut microbiome between patients with colorectal cancer and various control groups. The most consistent findings were for Fusobacterium, Porphyromonas, and Peptostreptococcus being significantly enriched in fecal and mucosal samples from patients with colorectal cancer. For the oral microbiome, significantly increased and decreased abundance was reported for Fusobacterium and Streptococcus, respectively, in patients with oral cancer compared with controls. Overall, although there was a large amount of evidence for some of these alterations, most require validation in high-quality, preferably prospective, epidemiologic studies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-20-0288

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The gut microbiome is a modifiable risk factor in multiple cancer types, including colorectal, gastric, and pancreatic cancers.

    “The gut microbiome is increasingly recognized as a modifiable risk factor in multiple cancer types, including colorectal, gastric, and pancreatic cancers [12,41–43]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [41]

    The Results (Overall significant findings; page not provided) report gut-microbiome differences in colorectal cancer and gastric-microbiome differences in gastric cancer. The Discussion (Barriers and challenges; page not provided) describes a possible link between gut microbial metabolites and pancreatic cancer risk, but identifies the oral microbiome in its pancreatic-cancer example. The review does not establish the gut microbiome as a modifiable risk factor for all three cancers: Clinical implications and future perspectives says evidence for cancer prevention is limited. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 130

  1. [1]Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome 2015; 3: 31 26229597 PMC4520061
  2. [2]Vogtmann E, Goedert JJ. Epidemiologic studies of the human microbiome and cancer. British journal of cancer 2016; 114: 237– 42 26730578 PMC4742587
  3. [3]Young VB. The role of the microbiome in human health and disease: an introduction for clinicians. BMJ 2017; 356: j831 28298355
  4. [4]Blum HE. The human microbiome. Adv Med Sci 2017; 62: 414– 20 28711782
  5. [5]Gevers D, Knight R, Petrosino JF, Huang K, McGuire AL, Birren BW, The Human Microbiome Project: a community resource for the healthy human microbiome. PLoS biology 2012; 10: e1001377 22904687 PMC3419203
  6. [6]Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. European journal of immunology 2015; 45: 17– 31 25328099
  7. [7]Daliri EB, Tango CN, Lee BH, Oh DH. Human microbiome restoration and safety. Int J Med Microbiol 2018; 308: 487– 97 29773467
  8. [8]Karkman A, Lehtimaki J, Ruokolainen L. The ecology of human microbiota: dynamics and diversity in health and disease. Ann N Y Acad Sci 2017; 1399: 78– 92 28319653
  9. [9]Proal AD, Lindseth IA, Marshall TG. Microbe-microbe and host-microbe interactions drive microbiome dysbiosis and inflammatory processes. Discovery medicine 2017; 23: 51– 60 28245427
  10. [10]Francescone R, Hou V, Grivennikov SI. Microbiome, inflammation, and cancer. Cancer journal (Sudbury, Mass) 2014; 20: 181– 9 PMC4112188 24855005
  11. [11]Fouad YA, Aanei C. Revisiting the hallmarks of cancer. American journal of cancer research 2017; 7: 1016– 36 28560055 PMC5446472
  12. [12]Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57– 70 10647931
  13. [14]Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 2016; 535: 376– 81 27409811
  14. [15]Aron-Wisnewsky J, Prifti E, Belda E, Ichou F, Kayser BD, Dao MC, Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut 2018 PMC7143256 29899081
  15. [19]Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nature medicine 2019; 25: 968– 76 31171880
  16. [20]Weng MT, Chiu YT, Wei PY, Chiang CW, Fang HL, Wei SC. Microbiota and gastrointestinal cancer. Journal of the Formosan Medical Association = Taiwan yi zhi 2019; 118 Suppl 1: S32– s41 30655033
  17. [21]Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 2000; 283: 2008– 12 10789670
  18. [22]Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700 19622552 PMC2714672
  19. [24]Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut 2018; 67: 120– 7 27742762 PMC5607064
  20. [25]Allali I, Delgado S, Marron PI, Astudillo A, Yeh JJ, Ghazal H, Gut microbiome compositional and functional differences between tumor and non-tumor adjacent tissues from cohorts from the US and Spain. Gut microbes 2015; 6: 161– 72 25875428 PMC4615176
  21. [26]Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer. JAMA oncology 2018; 4: 358– 65 29327043 PMC5885828
  22. [27]Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, Rodríguez-Hilario A, González H, Bondy J, 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, Human Papilloma Virus infection and surgical treatment. Oncotarget 2016; 7: 51320– 34 27259999 PMC5239478
  23. [28]Alanee S, El-Zawahry A, Dynda D, Dabaja A, McVary K, Karr M, A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis. The Prostate 2019; 79: 81– 7 30117171
  24. [30]Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. International journal of cancer 2018; 142: 769– 78 29023689
  25. [31]Henrich B, Rumming M, Sczyrba A, Velleuer E, Dietrich R, Gerlach W, Mycoplasma salivarium as a dominant coloniser of Fanconi anaemia associated oral carcinoma. PloS one 2014; 9: e92297 24642836 PMC3958540
  26. [32]Nasrollahzadeh D, Malekzadeh R, Ploner A, Shakeri R, Sotoudeh M, Fahimi S, Variations of gastric corpus microbiota are associated with early esophageal squamous cell carcinoma and squamous dysplasia. Scientific reports 2015; 5: 8820 25743945 PMC4351546
  27. [33]Chng KR, Chan SH, Ng AHQ, Li C, Jusakul A, Bertrand D, Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma. EBioMedicine 2016; 8: 195– 202 27428430 PMC4919562
  28. [34]Aviles-Jimenez F, Guitron A, Segura-Lopez F, Mendez-Tenorio A, Iwai S, Hernandez-Guerrero A, Microbiota studies in the bile duct strongly suggest a role for Helicobacter pylori in extrahepatic cholangiocarcinoma. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2016; 22: 178 e11– 22 26493848
  29. [36]Hieken TJ, Chen J, Hoskin TL, Walther-Antonio M, Johnson S, Ramaker S, The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. Scientific reports 2016; 6: 30751 27485780 PMC4971513
  30. [37]Audirac-Chalifour A, Torres-Poveda K, Bahena-Román M, Téllez-Sosa J, Martínez-Barnetche J, Cortina-Ceballos B, Cervical microbiome and cytokine profile at various stages of cervical cancer: A pilot study. PloS one 2016; 11 PMC4846060 27115350
  31. [38]Oh HY, Kim BS, Seo SS, Kong JS, Lee JK, Park SY, The association of uterine cervical microbiota with an increased risk for cervical intraepithelial neoplasia in Korea. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2015; 21: 674 e1– 9 25752224
  32. [39]Fang RL, Chen LX, Shu WS, Yao SZ, Wang SW, Chen YQ. Barcoded sequencing reveals diverse intrauterine microbiomes in patients suffering with endometrial polyps. American Journal of Translational Research 2016; 8: 1581– 92 27186283 PMC4859642
  33. [40]Mannell A, Plant M, Frolich J. The microflora of the oesophagus. Ann R Coll Surg Engl 1983; 65: 152– 4 6859774 PMC2494276
  34. [41]Half EE, Amir I, Naftali T, Gophna U, Konikoff FM. Gastric microbiota is altered in esophagitis and barrett’s esophagus and further modified by proton pump inhibitors. Gastroenterology 2012; 142: S442 24112768
  35. [42]Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, Mantilla A, Torres J. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Scientific reports 2014; 4: 4202 24569566 PMC3935187
  36. [43]Seo I, Jha BK, Suh SI, Suh MH, Baek WK. Microbial profile of the stomach: Comparison between normal mucosa and cancer tissue in the same patient. Journal of Bacteriology and Virology 2014; 44: 162– 9
  37. [44]Castano-Rodriguez N, Goh KL, Fock KM, Mitchell HM, Kaakoush NO. Dysbiosis of the microbiome in gastric carcinogenesis. Scientific reports 2017; 7: 15957 29162924 PMC5698432
  38. [45]Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut 2018; 67: 1024– 32 28765474 PMC5969346
  39. [46]Hu YL, Pang W, Huang Y, Zhang Y, Zhang CJ. The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics. Frontiers in cellular and infection microbiology 2018; 8: 433 30619779 PMC6299874
  40. [47]Li TH, Qin Y, Sham PC, Lau KS, Chu KM, Leung WK. Alterations in Gastric Microbiota After H. Pylori Eradication and in Different Histological Stages of Gastric Carcinogenesis. Scientific reports 2017; 7: 44935 28322295 PMC5359573
  41. [48]Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. EBioMedicine 2019; 40: 336– 48 30584008 PMC6412016
  42. [49]Wang L, Zhou J, Xin Y, Geng C, Tian Z, Yu X, Bacterial overgrowth and diversification of microbiota in gastric cancer. European journal of gastroenterology & hepatology 2016; 28: 261– 6 26657453 PMC4739309
  43. [50]Yu G, Hu N, Wang L, Wang C, Han XY, Humphry M, Gastric microbiota features associated with cancer risk factors and clinical outcomes: A pilot study in gastric cardia cancer patients from Shanxi, China. International journal of cancer 2017; 141: 45– 51 28319273 PMC5839466
  44. [51]Yu G, Torres J, Hu N, Medrano-Guzman R, Herrera-Goepfert R, Humphrys MS, Molecular Characterization of the Human Stomach Microbiota in Gastric Cancer Patients. Frontiers in cellular and infection microbiology 2017; 7: 302 28730144 PMC5498480
  45. [52]Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 2017; 66: 70– 8 26408641
  46. [53]Hosgood HD, 3rd, Sapkota AR, Rothman N, Rohan T, Hu W, Xu J, The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. Environ Mol Mutagen 2014; 55: 643– 51 24895247 PMC4217127
  47. [54]Cameron SJS, Lewis KE, Huws SA, Hegarty MJ, Lewis PD, Pachebat JA, A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PloS one 2017; 12: e0177062 28542458 PMC5444587
  48. [55]Carpagnano G Aspergillus spp. colonization in exhaled breath condensate of lung cancer patients from Puglia Region of Italy. European Respiratory Journal 2014; 44 PMC3975946 24548615
  49. [56]Tsay JJ, Wu BG, Badri MH, Clemente JC, Shen N, Meyn P, Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. American journal of respiratory and critical care medicine 2018; 198: 1188– 98 29864375 PMC6221574
  50. [57]Wang K, Huang Y, Zhang Z, Liao J, Ding Y, Fang X, A Preliminary Study of Microbiota Diversity in Saliva and Bronchoalveolar Lavage Fluid from Patients with Primary Bronchogenic Carcinoma. Medical science monitor: international medical journal of experimental and clinical research 2019; 25: 2819– 34 30994108 PMC6482867
  51. [58]Schmidt BL, Kuczynski J, Bhattacharya A, Huey B, Corby PM, Queiroz ELS, Changes in abundance of oral microbiota associated with oral cancer. PloS one 2014; 9 PMC4041887 24887397
  52. [59]Berkovits C, Toth A, Szenzenstein J, Deak T, Urban E, Gacser A, Analysis of oral yeast microflora in patients with oral squamous cell carcinoma. Springerplus 2016; 5: 1257 27536540 PMC4974209
  53. [60]Homann N, Tillonen J, Meurman JH, Rintamaki H, Lindqvist C, Rautio M, Increased salivary acetaldehyde levels in heavy drinkers and smokers: a microbiological approach to oral cavity cancer. Carcinogenesis 2000; 21: 663– 8 10753201
  54. [61]Banerjee S, Tian T, Wei Z, Peck KN, Shih N, Chalian AA, Microbial Signatures Associated with Oropharyngeal and Oral Squamous Cell Carcinomas. Scientific reports 2017; 7: 4036 28642609 PMC5481414
  55. [62]Bornigen D, Ren B, Pickard R, Li J, Ozer E, Hartmann EM, Alterations in oral bacterial communities are associated with risk factors for oral and oropharyngeal cancer. Scientific reports 2017; 7: 17686 29247187 PMC5732161
  56. [63]Hsiao JR, Chang CC, Lee WT, Huang CC, Ou CY, Tsai ST, The interplay between oral microbiome, lifestyle factors and genetic polymorphisms in the risk of oral squamous cell carcinoma. Carcinogenesis 2018; 39: 778– 87 29668903
  57. [64]Hu X, Zhang Q, Hua H, Chen F. Changes in the salivary microbiota of oral leukoplakia and oral cancer. Oral oncology 2016; 56: e6– 8 27026576
  58. [65]Lee WH, Chen HM, Yang SF, Liang C, Peng CY, Lin FM, Bacterial alterations in salivary microbiota and their association in oral cancer. Scientific reports 2017; 7: 16540 29184122 PMC5705712
  59. [66]Lim Y, Fukuma N, Totsika M, Kenny L, Morrison M, Punyadeera C. The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers. Frontiers in cellular and infection microbiology 2018; 8: 267 30123780 PMC6085444
  60. [67]Mok SF, Karuthan C, Cheah YK, Ngeow WC, Rosnah Z, Yap SF, The oral microbiome community variations associated with normal, potentially malignant disorders and malignant lesions of the oral cavity. The Malaysian journal of pathology 2017; 39: 1– 15 28413200
  61. [68]Perera M, Al-Hebshi NN, Perera I, Ipe D, Ulett GC, Speicher DJ, Inflammatory Bacteriome and Oral Squamous Cell Carcinoma. Journal of dental research 2018; 97: 725– 32 29630846
  62. [69]Wolf A, Moissl-Eichinger C, Perras A, Koskinen K, Tomazic PV, Thurnher D. The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study. Scientific reports 2017; 7: 5867 28725009 PMC5517471
  63. [71]Zhao H, Chu M, Huang Z, Yang X, Ran S, Hu B, Variations in oral microbiota associated with oral cancer. Scientific reports 2017; 7: 11773 28924229 PMC5603520
  64. [72]Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 2012; 61: 582– 8 21994333 PMC3705763
  65. [73]Torres PJ, Fletcher EM, Gibbons SM, Bouvet M, Doran KS, Kelley ST. Characterization of the salivary microbiome in patients with pancreatic cancer. PeerJ 2015; 2015 PMC4647550 26587342
  66. [74]Olson SH, Satagopan J, Xu Y, Ling L, Leong S, Orlow I, The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. Cancer causes & control: CCC 2017; 28: 959– 69 28762074 PMC5709151
  67. [75]Han S, Yang X, Qi Q, Pan Y, Chen Y, Shen J, Potential screening and early diagnosis method for cancer: Tongue diagnosis. International journal of oncology 2016; 48: 2257– 64 27035407 PMC4864042
  68. [76]Hu J, Han S, Chen Y, Ji Z. Variations of Tongue Coating Microbiota in Patients with Gastric Cancer. BioMed research international 2015; 2015: 173729 26457297 PMC4589578
  69. [77]Bi H, Tian Y, Song C, Li J, Liu T, Chen Z, Urinary microbiota - a potential biomarker and therapeutic target for bladder cancer. Journal of medical microbiology 2019; 68: 1471– 8 31418671
  70. [78]Bucevic Popovic V, Situm M, Chow CT, Chan LS, Roje B, Terzic J. The urinary microbiome associated with bladder cancer. Scientific reports 2018; 8: 12157 30108246 PMC6092344
  71. [80]Goedert JJ, Hua X, Bielecka A, Okayasu I, Milne GL, Jones GS, Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota. British journal of cancer 2018; 118: 471– 9 29360814 PMC5830593
  72. [82]Qi YF, Sun JN, Ren LF, Cao XL, Dong JH, Tao K, Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China. Digestive diseases and sciences 2019; 64: 1193– 203 30535886
  73. [83]Youssef O, Lahti L, Kokkola A, Karla T, Tikkanen M, Ehsan H, Stool Microbiota Composition Differs in Patients with Stomach, Colon, and Rectal Neoplasms. Digestive diseases and sciences 2018; 63: 2950– 8 29995183 PMC6182444
  74. [84]Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PloS one 2012; 7: e39743 22761885 PMC3386193
  75. [85]Mira-Pascual L, Cabrera-Rubio R, Ocon S, Costales P, Parra A, Suarez A, Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. Journal of Gastroenterology 2014; 50: 167– 79 24811328
  76. [86]Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 2017; 66: 633– 43 26992426 PMC5529966
  77. [87]Alexander JL, Scott A, Mroz A, Perdones-Montero A, McKenzie J, Rees DN, Mass spectrometry imaging (MSI) of microbiome-metabolome interactions in colorectal cancer. Gastroenterology 2016; 150: S23
  78. [88]Gao Z, Guo B, Gao R, Zhu Q, Wu W, Qin H. Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer. Mol Med Rep 2015; 12: 6119– 27 26238090
  79. [89]McCoy AN, Araújo-Pérez F, Azcárate-Peril A, Yeh JJ, Sandler RS, Keku TO. Fusobacterium Is Associated with Colorectal Adenomas. PloS one 2013; 8 PMC3546075 23335968
  80. [90]Burns MB, Lynch J, Starr TK, Knights D, Blekhman R. Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment. Genome medicine 2015; 7 26170900 PMC4499914
  81. [92]Marchesi JR, Dutilh BE, Hall N, Peters WHM, Roelofs R, Boleij A, Towards the human colorectal cancer microbiome. PloS one 2011; 6 PMC3101260 21647227
  82. [93]Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer research 2014; 74: 1311– 8 24385213 PMC4396185
  83. [94]Hale VL, Jeraldo P, Chen J, Mundy M, Yao J, Priya S, Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers. Genome medicine 2018; 10: 78 30376889 PMC6208080
  84. [95]Shah MS, DeSantis T, Yamal JM, Weir T, Ryan EP, Cope JL, Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer. PloS one 2018; 13: e0207002 30412600 PMC6226189
  85. [96]Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, Human gut microbiome and risk for colorectal cancer. Journal of the National Cancer Institute 2013; 105: 1907– 11 24316595 PMC3866154
  86. [98]Kasai C, Sugimoto K, Moritani I, Tanaka J, Oya Y, Inoue H, Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses. Oncology reports 2016; 35: 325– 33 26549775
  87. [100]Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y, Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microbial ecology 2013; 66: 462– 70 23733170
  88. [102]Allali I, Boukhatem N, Bouguenouch L, Hardi H, Boudouaya HA, Cadenas MB, Gut microbiome of Moroccan colorectal cancer patients. Medical microbiology and immunology 2018; 207: 211– 25 29687353 PMC6096775
  89. [103]Amitay EL, Werner S, Vital M, Pieper DH, Hofler D, Gierse IJ, Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. Carcinogenesis 2017; 38: 781– 8 28582482
  90. [104]Baxter NT, Ruffin MTt, Rogers MA, Schloss PD. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome medicine 2016; 8: 37 27056827 PMC4823848
  91. [106]Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PloS one 2016; 11: e0152126 27015276 PMC4807824
  92. [107]Zackular JP, Rogers MA, Ruffin MTt, Schloss PD. The human gut microbiome as a screening tool for colorectal cancer. Cancer prevention research (Philadelphia, Pa) 2014; 7: 1112– 21 PMC4221363 25104642
  93. [108]Ohigashi S, Sudo K, Kobayashi D, Takahashi O, Takahashi T, Asahara T, Changes of the intestinal microbiota, short chain fatty acids, and fecal pH in patients with colorectal cancer. Digestive diseases and sciences 2013; 58: 1717– 26 23306850
  94. [109]Amiot A, Dona A, Wijeyesekera A, Tournigand C, Lebaleur Y, Sobhani I, 1H HR NMR spectroscopy of fecal extracts enables detection of advanced colorectal neoplasia. United European Gastroenterology Journal 2015; 3: A266 26211820
  95. [110]Kanazawa K, Konishi F, Mitsuoka T, Terada A, Itoh K, Narushima S, Factors influencing the development of sigmoid colon cancer. Bacteriologic and biochemical studies. Cancer 1996; 77: 1701– 6 8608565
  96. [111]Richard ML, Liguori G, Lamas B, Brandi G, da Costa G, Hoffmann TW, Mucosa-associated microbiota dysbiosis in colitis associated cancer. Gut microbes 2018; 9: 131– 42 28914591 PMC5989788
  97. [112]Mori G, Rampelli S, Orena BS, Rengucci C, De Maio G, Barbieri G, Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis. Scientific reports 2018; 8: 10329 29985435 PMC6037773
  98. [113]Gao R, Gao Z, Huang L, Qin H. Gut microbiota and colorectal cancer. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 2017; 36: 757– 69 PMC5395603 28063002
  99. [115]Bratcher DF. 131 - Other Corynebacteria In: Long SS, Prober CG, Fischer M, editors. Principles and Practice of Pediatric Infectious Diseases (Fifth Edition): Elsevier; 2018 p 778– 81.e2.
  100. [116]Murphy EC, Frick IM. Gram-positive anaerobic cocci--commensals and opportunistic pathogens. FEMS microbiology reviews 2013; 37: 520– 53 23030831
  101. [117]Zhang G, Chen R, Rudney JD. Streptococcus cristatus modulates the Fusobacterium nucleatum-induced epithelial interleukin-8 response through the nuclear factor-kappa B pathway. J Periodontal Res 2011; 46: 558– 67 21521225
  102. [119]Wang D, Li Y, Zhong H, Ding Q, Lin Y, Tang S, Alterations in the human gut microbiome associated with Helicobacter pylori infection. FEBS open bio 2019 PMC6724102 31250988
  103. [120]Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell host & microbe 2013; 14: 195– 206 23954158 PMC3770529
  104. [121]Yu J, Zhao L, Zhao R, Long X, Coker OO, Sung JJY. The role of Parvimonas micra in intestinal tumorigenesis in germ-free and conventional APCmin/+ mice. Journal of Clinical Oncology 2019; 37: 531–
  105. [122]Groeger S, Jarzina F, Domann E, Meyle J. Porphyromonas gingivalis activates NFkappaB and MAPK pathways in human oral epithelial cells. BMC Immunol 2017; 18: 1 28056810 PMC5217430
  106. [123]Tsoi H, Chu ESH, Zhang X, Sheng J, Nakatsu G, Ng SC, Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. Gastroenterology 2017; 152: 1419– 33.e5 28126350
  107. [124]Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nature reviews Gastroenterology & hepatology 2018; 15: 111– 28 29018272 PMC5899973
  108. [125]Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. International journal of cancer 2016; 139: 1764– 75 27273788 PMC5493524
  109. [126]Li P, Shu Y, Gu Y. The potential role of bacteria in pancreatic cancer: A systematic review. Carcinogenesis 2020 32034405
  110. [127]Xie G, Raufman JP. Role of the Aryl Hydrocarbon Receptor in Colon Neoplasia. Cancers 2015; 7: 1436– 46 26264025 PMC4586780
  111. [128]Jin UH, Lee SO, Pfent C, Safe S. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC cancer 2014; 14: 498 25011475 PMC4226953
  112. [129]Fritz WA, Lin TM, Cardiff RD, Peterson RE. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis 2007; 28: 497– 505 17052998
  113. [130]Descamps HC, Herrmann B, Wiredu D, Thaiss CA. The path toward using microbial metabolites as therapies. EBioMedicine 2019; 44: 747– 54 31201140 PMC6606739
  114. [132]Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science (New York, NY) 2016; 352: 565– 9 PMC5240844 27126040
  115. [133]Smelov V, Arroyo Muhr LS, Bzhalava D, Brown LJ, Komyakov B, Dillner J. Metagenomic sequencing of expressed prostate secretions. Journal of medical virology 2014; 86: 2042– 8 24532541
  116. [134]Smelov V, Bzhalava D, Arroyo Muhr LS, Eklund C, Komyakov B, Gorelov A, Detection of DNA viruses in prostate cancer. Scientific reports 2016; 6: 25235 27121729 PMC4848500
  117. [135]Choo JM, Leong LE, Rogers GB. Sample storage conditions significantly influence faecal microbiome profiles. Scientific reports 2015; 5: 16350 26572876 PMC4648095
  118. [136]Costea PI, Zeller G, Sunagawa S, Pelletier E, Alberti A, Levenez F, Towards standards for human fecal sample processing in metagenomic studies. Nature biotechnology 2017; 35: 1069– 76 28967887
  119. [138]Hiergeist A, Glasner J, Reischl U, Gessner A. Analyses of Intestinal Microbiota: Culture versus Sequencing. ILAR journal 2015; 56: 228– 40 26323632
  120. [139]Maziarz M, Pfeiffer RM, Wan Y, Gail MH. Using standard microbiome reference groups to simplify beta-diversity analyses and facilitate independent validation. Bioinformatics (Oxford, England) 2018; 34: 3249– 57 PMC6157088 29668831
  121. [140]Le Cao KA, Gonzalez I, Dejean S. integrOmics: an R package to unravel relationships between two omics datasets. Bioinformatics (Oxford, England) 2009; 25: 2855– 6 PMC2781751 19706745
  122. [142]Filzmoser P, Hron K. Correlation Analysis for Compositional Data. Mathematical Geosciences 2008; 41: 905
  123. [143]Sinha R, Ahsan H, Blaser M, Caporaso JG, Carmical JR, Chan AT, Next steps in studying the human microbiome and health in prospective studies, Bethesda, MD, May 16–17, 2017. Microbiome 2018; 6: 210 30477563 PMC6257978
  124. [144]Bai J, Behera M, Bruner DW. The gut microbiome, symptoms, and targeted interventions in children with cancer: a systematic review. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 2017 29168036
  125. [145]Sinha R, Chen J, Amir A, Vogtmann E, Shi J, Inman KS, Collecting Fecal Samples for Microbiome Analyses in Epidemiology Studies. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2016; 25: 407– 16 PMC4821594 26604270
  126. [146]Vogtmann E, Chen J, Kibriya MG, Chen Y, Islam T, Eunes M, Comparison of Fecal Collection Methods for Microbiota Studies in Bangladesh. Applied and environmental microbiology 2017; 83 PMC5411505 28258145
  127. [147]Vogtmann E, Chen J, Amir A, Shi J, Abnet CC, Nelson H, Comparison of Collection Methods for Fecal Samples in Microbiome Studies. American journal of epidemiology 2017; 185: 115– 23 27986704 PMC5253972
  128. [148]Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nature biotechnology 2019; 37: 852– 7 PMC7015180 31341288
  129. [149]Minot SS, Krumm N, Greenfield NB. One Codex: A Sensitive and Accurate Data Platform for Genomic Microbial Identification. bioRxiv 2015: 027607
  130. [150]Overcoming hurdles in sharing microbiome data. Nature microbiology 2017; 2: 1573– 29176696

Cited by

Sorted by citations

Authors
Huybrechts, I., Zouiouich, S., Loobuyck, A., Vandenbulcke, Z., Vogtmann, E., Pisanu, S., Iguacel, I., Scalbert, A., Indave, I., Smelov, V., Gunter, M. J., & Michels, N.
Affiliations
  • Centre international de recherche sur le cancer (FR)
  • 1International Agency for Research on Cancer, Lyon, France.
  • Ghent University (BE)
  • National Cancer Institute (US)
  • University of Cagliari (IT)
  • Universidad de Zaragoza (ES)
  • World Health Organization Regional Office for Europe (DK)
ORCID
Venue
Cancer Epidemiology, Biomarkers & Prevention
Publisher
American Association for Cancer Research (AACR)
Published
2020-10-01
Volume
29
Issue
10
Pages
1856-1868
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
DOI
10.1158/1055-9965.epi-20-0288
PMC
PMC7541789
OpenAlex
W3045690027
Cited by
80
References
18
Citations by year
2026: 8 · 2025: 16 · 2024: 7 · 2023: 18 · 2022: 16 · 2021: 13 · 2020: 2
FWCI
1.20
Type
journal article
Language
en
Open access
Locations
  • Cancer Epidemiology Biomarkers & Prevention (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Funders
Research Foundation (12H1519N, FWO3EO2015004301)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
Keywords
human microbiome, cancer risk, gut microbiota, colorectal cancer, oral microbiota, oral cancer, Fusobacterium, Porphyromonas, Peptostreptococcus, Streptococcus, microbial community composition, carcinogenesis
MeSH terms
Gastrointestinal Microbiome, Humans, Neoplasms, Risk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review